Analyzing Sight Sciences (SGHT) & Its Peers

Sight Sciences (NASDAQ:SGHT – Get Rating) is one of 216 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its peers? We will compare Sight Sciences to similar companies based on the strength of its earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and risk.

Valuation and Earnings

This table compares Sight Sciences and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Sight Sciences	$48.96 million	-$62.96 million	-3.40
Sight Sciences Competitors	$1.15 billion	$84.66 million	-537.77

Sight Sciences’ peers have higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

60.8% of Sight Sciences shares are owned by institutional investors. Comparatively, 51.2% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 14.4% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Sight Sciences and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-134.02%	-51.67%	-33.54%
Sight Sciences Competitors	-748.20%	-65.14%	-19.63%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Sight Sciences and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	0	0	5	0	3.00
Sight Sciences Competitors	1308	4640	8023	221	2.50

Sight Sciences presently has a consensus target price of $31.00, suggesting a potential upside of 194.68%. As a group, “Surgical & medical instruments” companies have a potential upside of 54.70%. Given Sight Sciences’ stronger consensus rating and higher possible upside, research analysts clearly believe Sight Sciences is more favorable than its peers.

Summary

Sight Sciences beats its peers on 7 of the 12 factors compared.

About Sight Sciences (Get Rating)

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.

Want More Great Investing Ideas?